AgriMetis

Blog Posts

L-Glufosinate Process Patent Issued to AgriMetis

LUTHERVILLE, MD – December 7, 2017 – AgriMetis, LLC today announced that its patent application, drawn to methods of making its broad-spectrum herbicide product, L-Glufosinate (Glu-L™), has been issued as U.S. Patent No. 9,834,802 by the U.S. Patent and Trademark Office.  The international application filed by the company is still pending.  

The patent claims are drawn to a two-step process for the production of substantially pure L-Glufosinate. This novel enzymatic process substantially increases the proportion of the active L-Glufosinate isomer in the mixture with D-Glufosinate.

Glu-L is an improved alternative to the commercial racemic glufosinate being manufactured and sold.  The milestone achievement described in this patent exemplifies how the AgriMetis approach of combining biology and chemistry can lead to differentiated active ingredients in a well-studied agricultural crop protection market. 

“We are especially proud of this important development as it will provide farmers the potential for more efficient and improved products for broad spectrum weed control,” said Steven Tuttle, President and CEO of AgriMetis. 

About AgriMetis:
In an evolving and growing global population, there continues to be an increasing demand for sustainable, crop protection products. AgriMetis is committed to working with leading agriculture companies and businesses to fill this emerging need.

Our mission is to innovate sustainable crop protection products through leading edge and advanced discovery, development and delivery methods.

The AgriMetis technology platform is at the interface of biology, biochemistry, and chemistry. AgriMetis’ scientific approach is multidisciplinary and integrated, which allows AgriMetis to exploit areas of chemical space and production routes that are inaccessible to others.

AgriMetis was formed in March 2014 and completed a Series B financing in December 2016 to fund agriculture chemical research and development by applying a biopharmaceutical model. With headquarters near Baltimore, Maryland, AgriMetis continues to grow and develop its technologies and capabilities.

For more information, please visit our website at http://www.agrimetis.com

This press release contains “forward-looking statements” concerning the development of AgriMetis’ products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. AgriMetis undertakes no obligation to update any forward-looking statements for any reason.

Laurie Gunther